血浆SARS-CoV-2核衣壳抗原水平与住院COVID-19患者进展为重症相关
该前瞻性观察性队列纳入2020年3月至2021年8月住院的256例COVID-19患者,检测入院72小时内(D0)血浆SARS-CoV-2核衣壳抗原(N抗原)浓度。D0 N抗原在84%受试者中可检测到,与RAGE(r=0.61)、IL-10(r=0.59)、IP-10(r=0.59,校正P=0.01)相关。N抗原每升高500 pg/mL,第7天WHO ordinal量表状态恶化的校正OR为1.05(95%CI 1.03-1.08)。D0 N抗原≥1000 pg/mL预测第7天WHO ordinal量表较基线恶化的敏感性77%、特异性59%(AUROC 0.68),阳性预测值23%、阴性预测值93%。D0 N抗原浓度与ICU入住和28天机械通气独立相关,但与28天死亡无关。
要点
- 住院COVID-19患者入院72小时内血浆N抗原≥1000 pg/mL预测第7天WHO ordinal量表恶化的阴性预测值93%,可用于识别不太可能进展为重症的患者。
- 血浆N抗原每升高500 pg/mL,第7天WHO ordinal量表状态恶化的校正OR为1.05(95%CI 1.03-1.08)。
- N抗原≥1000 pg/mL预测第7天WHO ordinal量表恶化的敏感性77%、特异性59%(AUROC 0.68),阳性预测值23%。
- D0 N抗原浓度与ICU入住和28天机械通气独立相关,但与28天死亡无关。
- D0 N抗原在84%受试者中可检测到,与RAGE(r=0.61)、IL-10(r=0.59)、IP-10(r=0.59,校正P=0.01)相关。
适用人群与场景
- 2020年3月至2021年8月入住的前瞻性观察性队列中的256例住院COVID-19患者,于入院72小时内采集首个研究血浆样本(D0)。
诊断标准与关键阈值
- 采用外部推导的「高抗原」截断值:血浆N抗原≥1000 pg/mL。
- 主要结局为第7天临床恶化,采用改良世界卫生组织(WHO)ordinal量表评估。
研究设计与关键结果
- 前瞻性观察性队列,256例住院COVID-19患者,D0(入院72小时内)血浆N抗原在84%受试者中可检测到。
- 血浆N抗原与RAGE(r=0.61)、IL-10(r=0.59)、IP-10(r=0.59)相关,校正P=0.01。
- 主要结局:N抗原每升高500 pg/mL,第7天WHO ordinal量表状态恶化的校正OR为1.05(95%CI 1.03-1.08)。
- D0 N抗原≥1000 pg/mL预测第7天WHO ordinal量表较基线恶化的敏感性77%、特异性59%(AUROC 0.68),阳性预测值23%、阴性预测值93%。
- D0 N抗原浓度与ICU入住和28天机械通气独立相关,但与28天死亡无关。
证据类型、等级与局限
- 证据类型:前瞻性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,血浆N抗原水平易于检测,可为了解COVID-19的发病机制和预后提供重要信息。
- 作者认为,在住院早期检测N抗原水平可能改善风险分层,尤其有助于识别不太可能进展为重症的患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Studies quantifying SARS-CoV-2 have focused on upper respiratory tract or plasma viral RNA with inconsistent association with clinical outcomes. The association between plasma viral antigen levels and clinical outcomes has not been previously studied. Our aim was to investigate the relationship between plasma SARS-CoV-2 nucleocapsid antigen (N-antigen) concentration and both markers of host response and clinical outcomes.
METHODS: SARS-CoV-2 N-antigen concentrations were measured in the first study plasma sample (D0), collected within 72 h of hospital admission, from 256 subjects admitted between March 2020 and August 2021 in a prospective observational cohort of hospitalized patients with COVID-19. The rank correlations between plasma N-antigen and plasma biomarkers of tissue damage, coagulation, and inflammation were assessed. Multiple ordinal regression was used to test the association between enrollment N-antigen plasma concentration and the primary outcome of clinical deterioration at one week as measured by a modified World Health Organization (WHO) ordinal scale. Multiple logistic regression was used to test the association between enrollment plasma N-antigen concentration and the secondary outcomes of ICU admission, mechanical ventilation at 28 days, and death at 28 days. The prognostic discrimination of an externally derived "high antigen" cutoff of N-antigen ≥ 1000 pg/mL was also tested.
RESULTS: N-antigen on D0 was detectable in 84% of study participants. Plasma N-antigen levels significantly correlated with RAGE (r = 0.61), IL-10 (r = 0.59), and IP-10 (r = 0.59, adjusted p = 0.01 for all correlations). For the primary outcome of clinical status at one week, each 500 pg/mL increase in plasma N-antigen level was associated with an adjusted OR of 1.05 (95% CI 1.03-1.08) for worse WHO ordinal status. D0 plasma N-antigen ≥ 1000 pg/mL was 77% sensitive and 59% specific (AUROC 0.68) with a positive predictive value of 23% and a negative predictive value of 93% for a worse WHO ordinal scale at day 7 compared to baseline. D0 N-antigen concentration was independently associated with ICU admission and 28-day mechanical ventilation, but not with death at 28 days.
CONCLUSIONS: Plasma N-antigen levels are readily measured and provide important insight into the pathogenesis and prognosis of COVID-19. The measurement of N-antigen levels early in-hospital course may improve risk stratification, especially for identifying patients who are unlikely to progress to severe disease.
参考来源
- Wick KD, Leligdowicz A, Willmore A, et al. Plasma SARS-CoV-2 nucleocapsid antigen levels are associated with progression to severe disease in hospitalized COVID-19. Crit Care. 2022. PMID: 36104754. doi:10.1186/s13054-022-04153-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。